Natus Sensory
Private medtech company building a broad sensory and newborn-care portfolio across hearing, vision, balance, NICU monitoring, and neonatal workflow products.
What They Do
Natus Sensory sells clinical hardware, software, and services used in hearing and balance assessment, pediatric vision screening, and newborn care. In the neonatal segment, its portfolio spans hearing and vision screening, jaundice phototherapy, NicView camera-based family connection, and Neometrics case-management software; the 2026 acquisitions of Keriton and TheraB Medical extend that footprint into feeding management and wearable phototherapy. The company operates as a private carve-out backed by ARCHIMED, formed from the 2022 take-private of Natus Medical and subsequent split into Natus Neuro and Natus Sensory.
Competitive Position
Not a startup-style company; strategic significance to PHD is as an acquirer and category shaper in neonatal and sensory care. Competes with GE HealthCare, Masimo, and Philips in newborn monitoring hardware, and with AngelEye Health in NICU family engagement. Its 2026 acquisition pace — Keriton and TheraB within 14 days — signals active platform consolidation.
Funding Rounds
No funding rounds on record for this company.